MENU
+Compare
RNLXY
Stock ticker: OTC
AS OF
Oct 3 closing price
Price
$0.26
Change
-$0.01 (-3.70%)
Capitalization
47.26M

RNLXY stock forecast, quote, news & analysis

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally... Show more

RNLXY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. RNLXY showed earnings on March 18, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for RNLXY with price predictions
Oct 03, 2025

RNLXY saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for RNLXY moved out of overbought territory on September 16, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 42 similar instances where the indicator exited the overbought zone. In of the 42 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for RNLXY moved out of overbought territory on September 22, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on October 03, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RNLXY as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNLXY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RNLXY broke above its upper Bollinger Band on September 19, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

RNLXY moved above its 50-day moving average on September 12, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for RNLXY crossed bullishly above the 50-day moving average on September 15, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RNLXY advanced for three days, in of 228 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 108 cases where RNLXY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RNLXY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (20.375). P/E Ratio (0.000) is within average values for comparable stocks, (85.970). RNLXY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.823). RNLXY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.028). P/S Ratio (7.758) is also within normal values, averaging (69.060).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNLXY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 2.35B. The market cap for tickers in the group ranges from 52.04K to 49.13B. VEEV holds the highest valuation in this group at 49.13B. The lowest valued company is PPRG at 52.04K.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was 4%. For the same Industry, the average monthly price growth was 12%, and the average quarterly price growth was 39%. ONMD experienced the highest price growth at 142%, while MITI experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 92%. For the same stocks of the Industry, the average monthly volume growth was 127% and the average quarterly volume growth was 40%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 71
Price Growth Rating: 55
SMR Rating: 86
Profit Risk Rating: 94
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
RNLXY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Profile
Fundamentals
Details